Drug
Tifeglipron
Tifeglipron: highest development phase Phase 2, developed by Roche. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Roche
Trials
| Drug | Phase | Indication |
|---|---|---|
| Tifeglipron NCT07112872 | Phase 2 | Type 2 Diabetes Mellitus |
| Tifeglipron NCT07081958 | Phase 2 | Obesity or Overweight |
Latest
No recent events.
Follow Tifeglipron on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.